Cyclacel Pharmaceuticals, Inc. financial data

Symbol
CYCC, CYCCP on Nasdaq
Location
200 Connell Drive, Suite 1500, Berkeley Heights, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 97.8 % -20.3%
Debt-to-equity 2.23K % +560%
Return On Equity -3.64K % -333%
Return On Assets -156 % +12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 207M shares +15628%
Common Stock, Shares, Outstanding 207M shares +15628%
Entity Public Float 2.52M USD -55.1%
Common Stock, Value, Issued 204K USD +20300%
Weighted Average Number of Shares Outstanding, Basic 12.6M shares +23.8%
Weighted Average Number of Shares Outstanding, Diluted 12.6M shares +23.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.68M USD -71.3%
General and Administrative Expense 4.21M USD +166%
Operating Income (Loss) -12.7M USD +43.6%
Nonoperating Income (Expense) 4.91M USD +8909%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.78M USD +65.8%
Income Tax Expense (Benefit) -782K USD +73.9%
Net Income (Loss) Attributable to Parent -8.35M USD +57.6%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.45M USD +23.3%
Other Assets, Current 194K USD -46.8%
Assets, Current 3.71M USD -23.2%
Property, Plant and Equipment, Net 1K USD -85.7%
Operating Lease, Right-of-Use Asset 19K USD -75.9%
Assets 3.73M USD -39.4%
Accounts Payable, Current 114K USD -97.8%
Accrued Liabilities, Current 549K USD -82.6%
Liabilities, Current 663K USD -92.1%
Operating Lease, Liability, Noncurrent 9K USD -57.1%
Liabilities 672K USD -92%
Accumulated Other Comprehensive Income (Loss), Net of Tax -891K USD +1.87%
Retained Earnings (Accumulated Deficit) -440M USD -2.14%
Stockholders' Equity Attributable to Parent 3.06M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.06M USD
Liabilities and Equity 3.73M USD -39.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.25M USD -572%
Net Cash Provided by (Used in) Financing Activities 3.65M USD
Net Cash Provided by (Used in) Investing Activities -6K USD -50%
Common Stock, Shares Authorized 250M shares +150%
Common Stock, Shares, Issued 207M shares +15628%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 313K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.14M USD -7.13%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD
Deferred Tax Assets, Valuation Allowance 59.8M USD +4.36%
Deferred Tax Assets, Gross 59.8M USD +4.36%
Operating Lease, Liability 5K USD
Depreciation 2K USD -75%
Payments to Acquire Property, Plant, and Equipment 6K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.45M USD +61.5%
Lessee, Operating Lease, Liability, to be Paid 22K USD -74.7%
Property, Plant and Equipment, Gross 427K USD -0.47%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 5K USD -92.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 59.4M USD +4.11%
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 443M USD +3.12%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.06M USD +61.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%